New hypotheses for large-scale epigenome alterations in somatic cancer cells: A role for male germ-cell-specific regulators

Epigenomics

Volumn 1, Issue 1, 2009, Pages 153-161

  Rousseaux, Sophie ^a   Khochbin, Saadi ^a  

^a INSERM   (France)

Author keywords

Biomarker; BRDT; Cancer; Chromatin; GAGE; Histone immunotherapy; MAGE; SP011; Spermatogenesis; Spermiogenesis

Indexed keywords

TUMOR MARKER;

ARTICLE; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS; GERM CELL; HUMAN; HUMAN GENOME; MALE; MEIOSIS; METABOLISM; PHYSIOLOGY; SPERMATOGENESIS; TESTIS TUMOR;

CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GENOME, HUMAN; GERM CELLS; HUMANS; MALE; MEIOSIS; SPERMATOGENESIS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952499015     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.09.1     Document Type: Review

References (95)

1. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell 128, 669-681 (2007). (Pubitemid 46273573)
2. Bhaumik SR, Smith E, Shilatifard A: Covalent modifications of histones during development and disease pathogenesis. Nat. Struct. Mot. Biol. 14, 1008-1016 (2007). (Pubitemid 350060343)
3. Li B, Carey M, Workman JL: The role of chromatin during transcription. Cell 128, 707-719 (2007). (Pubitemid 46273570)
4. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298 (2007). (Pubitemid 46439286)
5. Baylin SB: DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol.2 (Suppl. 1), S4-11 (2005).
6. Fraga MF, Ballestar E, A Villar-Garea et al.: Loss of acetylation at Lysl6 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391-400 (2005).
7. Miremadi A, Oestergaard MZ, Pharoah P.D., Caldas C: Cancer genetics of epigenetic genes. Hum. Mol. Genet. 16(Spec. 1), R28-R49 (2007). (Pubitemid 47241841)
8. Caron C, Govin J, Rousseaux S., Khochbin S: How to pack the genome for a safe trip. Prog. Mol. Subcell. Biol. 38, 65-89 (2005).
9. Govin J, Caron C, Lestrat C., Rousseaux S, Khochbin S: The role of histones in chromatin remodelling during mammalian spermiogenesis. Eur. J. Biochem. 271, 3459-3469 (2004). (Pubitemid 39215336)
10. Rousseaux S, Caron C, Govin J., Lestrat C, Faure AK, Khochbin S: Establishment of male-specific epigenetic information. Gene 345, 139-153 (2005). (Pubitemid 40228822)
11. Hazzouri M, C Pivot-Pajot, Faure AK et al.: Regulated hyperacetylation of core histones during mouse spermatogenesis: involvement of histone deacetylases. Eur, J. Cell Biol. 79, 950-960 (2000). (Pubitemid 32000729)
12. Govin J, Escoffier E, Rousseaux S et al.: Pericentric heterochromatin reprogramming by new histone variants during mouse spermiogenesis. J. Cell Biol. 176, 283-294 (2007). (Pubitemid 46184880)
13. Boussouar F, Rousseaux S, Khochbin S: A new insight into male genome reprogramming by histone variants and histone code. Cell Cycle 7(22), 3499-3502 (2008).
14. Govin J, Lestrat C, Caron C., Pivot-Pajot C, Rousseaux S, Khochbin S: Histone acetylation-mediated chromatin compaction during mouse spermatogenesis. Ernst Schering Res. Found. Workshop 57, 155-172 (2006).
15. Pivot-Pajot C., Caron C, Govin J., Vion A, Rousseaux S, Khochbin S: Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol. Cell Biol. 23, 5354-5365 (2003). (Pubitemid 36950890)
16. Wallace JA, Felsenfeld G: We gather together: insulators and genome organization. Curr. Opin. Genet. Dev. 17, 400-407 (2007). (Pubitemid 350016897)
17. Loukinov D, Ghochikyan A, Mkrtichyan M et al.: Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J. Cell Biochem. 98, 1037-1043 (2006). (Pubitemid 44128346)
18. Loukinov DI, Pugacheva E, Vatolin S et al.: BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl Acad. Sci. USA 99, 6806-6811 (2002). (Pubitemid 34526213)
19. D'Arcy V., Abdullaev ZK, Pore N et al.: The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin. Cancer Res. 12, 5978-5986 (2006). (Pubitemid 44703757)
20. D'Arcy V., Pore N, Docquier F et al.: BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br. J. Cancer 98, 571-579 (2008). (Pubitemid 351214517)
21. Kholmanskikh O, Loriot A, Brasseur F., De Plaen E, De Smet C: Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int. J. Cancer 122, 777-784 (2008).
22. Risinger JI, Chandramouli GV, Maxwell GL et al.: Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin. Cancer Res. 13, 1713-1719(2007). (Pubitemid 46952936)
23. Vatolin S, Abdullaev Z, Pack SD et al.: Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-AI and reactivation of other cancer-testis genes. Cancer Res. 65, 7751-7762(2005). (Pubitemid 41297250)
24. Hong J.A., Kang Y, Abdullaev Z et al.: Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 65, 7763-7774 (2005). (Pubitemid 41297251)
25. Kang Y, Hong JA, Chen G.A., Nguyen DM, Schrump DS: Dynamic transcriptional regulatory complexes including BORIS, CTCF and Spl modulate NY-ESO-1 expression in lung cancer cells. Oncogene 26, 4394-4403 (2007). (Pubitemid 47014459)
26. Kondo T, Zhu X, Asa S.L., Ezzat S: The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin. Cancer Res. 13, 4713-4720 (2007). (Pubitemid 47294777)
27. Yang B, Wu J, Maddodi N., Ma Y, Set aluri V, Longley BJ: Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J. Invest. Dermatol. 127, 2123-2128 (2007). (Pubitemid 47258482)
28. Yang B, O'Herrin SM, Wu J et al.: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67, 9954-9962 (2007). (Pubitemid 47621245)
29. Monte M, Simonatto M, Peche LY et al.: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA 103, 11160-11165 (2006). (Pubitemid 44156489)
30. Laduron S, Deplus R, Zhou S et al.: MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. 32, 4340-4350 (2004). (Pubitemid 39232306)
31. Shang E, Nickerson HD, Wen D, Wang X., Wolgemuth DJ: The first bromodomain of Brdt, a testis-specific member of the BET sub-family of doubie-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 134, 3507-3515 (2007). (Pubitemid 350028369)
32. Scanlan MJ, Altorki NK, Gure AO et al.: Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 150, 155-164 (2000). (Pubitemid 30125849)
33. Schaefer CB, Ooi SK, Bestor T.H., Bourc'his D: Epigenetic decisions in mammalian germ cells. Science 316, 398-399 (2007). (Pubitemid 46651477)
34. Gokul G, Gautami B, Malathi S et al.: DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Epigenetics 2, 80-85 (2007). (Pubitemid 351682000)
35. Ooi SK, Qiu C, Bernstein E et al.: DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714-717 (2007). (Pubitemid 47236857)
36. Keeney S, Giroux CN, Kleckncr N: Meiosis-specific DNA double-strand breaks are catalyzed by Spoll, a member of a widely conserved protein family. Cell 88, 375-384 (1997). (Pubitemid 27131379)
37. Kisseleva-Romanova E., Lopreiato R, Baudin-Baillieu A et al.: Yeast homolog of a cancer-testis antigen defines a new transcription complex. EMBOJ. 25, 3576-3585 (2006). (Pubitemid 44264868)
38. Park JH, Lin ML, Nishidate T, Nakamura Y., Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 66, 9186-9195 (2006). (Pubitemid 44521139)
39. Weber M, Hellmann I, Stadler MB et al.: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39(4), 457-466 (2007). (Pubitemid 46514772)
40. Lim JH, Kim SP, Gabrielson E, Park Y.B., ParkJW, Kwon TK: Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation. Int. J. Cancer 116, 200-206 (2005). (Pubitemid 40967256)
41. Dodge JE, Kang YK, Beppu H, Lei H., Li E: Histone H3-K9 methyltransferase ESET is essential for early development. Mol. Cell Biol. 24, 2478-2486 (2004). (Pubitemid 38326002)
42. Tachibana M, Ueda J, Fukuda M et al.: Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 19, 815-826 (2005).
43. Collins RE, Tachibana M, Tamaru H et al.: In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases. J. Biol. Chem. 280, 5563-5570 (2005). (Pubitemid 40280034)
44. DAlessio AC, Weaver ICSzyfM: Acetylation-induced transcription is required for active DNA demerhylation in methylation-silenced genes. Mol. Cell Biol. 27, 7462-7474 (2007). (Pubitemid 350033653)
45. De Smet C., Loriot A, Boon T: Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol. Cell Biol. 24, 4781-4790 (2004). (Pubitemid 38668044)
46. Loriot A, De Plaen E, Boon T, De Smet C: Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem. 281, 10118-10126(2006). (Pubitemid 43864547)
47. James SR, Link PA, Karpf AR: Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 25, 6975-6985 (2006). (Pubitemid 44684838)
48. Costa FF, Le Blanc K, Brodin B: Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25, 707-711 (2007). (Pubitemid 46354230)
49. Kalejs M, Erenpreisa J: Cancer/testis antigens and gametogenesis: a review and 'brainstorming' session. Cancer Cell Int. 5, 4 (2005).
50. Meklat F, Li Z, Wang Z et al.: Cancer-testis antigens in haematological malignancies. Br. J. Haematol. 136, 769-776 (2007). (Pubitemid 46348406)
51. Scanlan MJ, Gure AO, Jungbluth A.A., Old LJ, Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188, 22-32 (2002). (Pubitemid 35398862)
52. Scanlan MJ, Simpson AJ, Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4, 1 (2004).
53. Simpson AJ, Caballero OL, Jungbluth A, Chen Y.T., Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615-625 (2005). (Pubitemid 41081387)
54. Hofmann O, Caballero OL, Stevenson BJ et al.: Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA 105, 20422-20427 (2008).
55. Boel P, Wildmann C, Sensi ML et al.: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167-175 (1995).
56. De Backer O., Arden KC, Boretti M et al.: Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 59, 3157-3165 (1999). (Pubitemid 29316016)
57. van der Bruggen P, Bastin J, Gajewski T et al.: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24, 3038-3043 (1994).
58. van der Bruggen P, Traversari C, Chomez P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991). (Pubitemid 21917508)
59. Chen YT, Gure AO, Tsang S et al.: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl Acad. Sci. USA 95, 6919-6923 (1998). (Pubitemid 28278082)
60. Sahin U, Tureci O, Schmitt H et al.: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810-11813 (1995). (Pubitemid 26014201)
61. Tureci O, Chen YT, Sahin U et al.: Expression of SSX genes in human tumors. Int. J. Cancerll, 19-23 (1998). (Pubitemid 28308546)
62. Chen YT, Scanlan MJ, Sahin U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914-1918 (1997). (Pubitemid 27113936)
63. Bock-Axelsen J., Lotem J, Sachs L., Domany E: Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc. Natl Acad. Sci. USA (2007).
64. Scanlan MJ, Gordon CM, Williamson B et al.: Identification of cancer/testis genes by database mining and mRNA expression analysis. Int. J. Cancer 98, 485-492 (2002). (Pubitemid 34208547)
65. Atanackovic D, Blum I, Cao Y et al.: Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol. Ther. 5, 1218-1225 (2006). (Pubitemid 44772241)
66. Grizzi F, Gaetani P, Franceschini B et al.: Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer 6, 23 (2006).
67. Hoeppner LH, Dubovsky JA, Dunphy E.J., McNeel DG: Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun. 6, 1 (2006).
68. Hoffmann MJ, Muller M, Engers R., Schulz WA: Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem. Pharmacol- 72, 1577-1588 (2006). (Pubitemid 44666737)
69. Okada T, Akada M, Fujita T et al.: A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin. Cancer Res. 12, 191-197 (2006). (Pubitemid 43166194)
70. Pavoni E, Pucci A, Vaccaro P et al.: A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage display. Cancer Detect. Prev. 30, 248-256 (2006). (Pubitemid 44163059)
71. Sahin U, Koslowski M, Tureci O et al.: Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 6, 3916-3922 (2000).
72. Sahin U, Tureci O, Chen YT et al.: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basi for polyvalent CT vaccine strategies. Int. J. Cancer7S, 387-389 (1998). (Pubitemid 28445380)
73. Taylor M, Bolton LM, Johnson P, Elliott T., Murray N: Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res. 9, R46 (2007).
74. Westbrook VA, Schoppee PD, Diekman AB et al.: Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin. Cancer Res. 10, 101-112 (2004). (Pubitemid 38114168)
75. Woloszynska-Read A., James SR, Link P.A., Yu J., Odunsi K, Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 7, 21 (2007).
76. Atanackovic D, Arfsten J, Cao Y et al.: Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109, 1103-1112 (2007). (Pubitemid 46220657)
77. Condomines M, Hose D, Raynaud P et al.: Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178, 3307-3315 (2007). (Pubitemid 46333216)
78. Cooper CD, Liggins AP, Ait-Tahar K, Roncador G., Banham AH, Pulford K: PASDI, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia 20, 2172-2174 (2006). (Pubitemid 44782844)
79. Greiner J, Schmitt M: Cancer testis/germline antigens (CT/CG-antigens) in leukemias. Leuk. Res. 31, 1-3(2007). (Pubitemid 44709752)
80. Heidebrecht HJ, Claviez A, Kruse ML et al.: Characterization and expression of CT45 in Hodgkin's lymphoma. Clin. Cancer Res. 12, 4804-4811 (2006). (Pubitemid 44338564)
81. Meklat F, Zhang Y, Shahriar M et al.: Identification of protamine 1 as a novel cancer-testis antigen in early chronic lymphocytic leukaemia. Br. J. Haematol. 144, 660-666 (2009).
82. Taylor BJ, Reiman T, Pittman JA et al.: SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J. Immunother. 28, 564-575 (2005). (Pubitemid 41533090)
83. * responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl Acad. Sci. USA 101, 9363-9368 (2004). (Pubitemid 38812881)
84. *) T cell responses in humans. Proc. Natl Acad. Sci. USA 101, 10697-10702 (2004). (Pubitemid 38955805)
85. * cancers. Proc. Natl Acad. Sci. USA 97, 12198-12203 (2000).
86. Jager E, Karbach J, Gnjatic S et al.: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103, 14453-14458 (2006). (Pubitemid 44484771)
87. Marchand M, Punt CJ, Aamdal S et al.: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39, 70-77 (2003). (Pubitemid 36005427)
88. Marchand M, van Baren N, Weynants P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGES and presented by HLA-A1. Int. J. Cancer 80, 219-230 (1999). (Pubitemid 29001725)
89. Odunsi K, Qian F, Matsuzaki J et al.: Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA 104, 12837-12842 (2007). (Pubitemid 47255241)
90. Szmania S, Gnjatic S, Tricot G et al.: Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J. Immunother. 30, 847-854 (2007). (Pubitemid 350295364)
91. Susumu S, Nagata Y, Ito S et al.: Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Sci. 99, 107-112 (2008). (Pubitemid 350239038)
92. Karpf AR: Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr. Opin. Mol. Ther. 9, 231-241 (2007). (Pubitemid 46944314)
93. Natsume A, Wakabayashi T, Tsujimura K et al.: The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int. J. Cancer 122, 2542-2553 (2008). (Pubitemid 351590488)
94. Govin J, Caron C, Rousseaux S., Khochbin S: Testis-specific histone H3 expression in somatic cells. Trends Biochem. Sci. 30, 357-359 (2005). (Pubitemid 40942029)
95. Cancer Immunity website www.cancerimmunity.org/CTdatabase/